BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34635660)

  • 1. Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination.
    Setton J; Selenica P; Mukherjee S; Shah R; Pecorari I; McMillan B; Pei IX; Kemel Y; Ceyhan-Birsoy O; Sheehan M; Tkachuk K; Brown DN; Zhang L; Cadoo K; Powell S; Weigelt B; Robson M; Riaz N; Offit K; Reis-Filho JS; Mandelker D
    NPJ Breast Cancer; 2021 Oct; 7(1):135. PubMed ID: 34635660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
    Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
    BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
    Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J
    JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
    Golmard L; Castéra L; Krieger S; Moncoutier V; Abidallah K; Tenreiro H; Laugé A; Tarabeux J; Millot GA; Nicolas A; Laé M; Abadie C; Berthet P; Polycarpe F; Frébourg T; Elan C; de Pauw A; Gauthier-Villars M; Buecher B; Stern MH; Stoppa-Lyonnet D; Vaur D; Houdayer C
    Eur J Hum Genet; 2017 Dec; 25(12):1345-1353. PubMed ID: 29255180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
    Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
    Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
    Song H; Dicks E; Ramus SJ; Tyrer JP; Intermaggio MP; Hayward J; Edlund CK; Conti D; Harrington P; Fraser L; Philpott S; Anderson C; Rosenthal A; Gentry-Maharaj A; Bowtell DD; Alsop K; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Høgdall E; Høgdall CK; Jensen A; Kjaer SK; Lubiński J; Huzarski T; Jakubowska A; Gronwald J; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Odunsi K; Goode EL; Menon U; Jacobs IJ; Gayther SA; Pharoah PD
    J Clin Oncol; 2015 Sep; 33(26):2901-7. PubMed ID: 26261251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination-deficient mutation cluster in tumor suppressor
    Prakash R; Rawal Y; Sullivan MR; Grundy MK; Bret H; Mihalevic MJ; Rein HL; Baird JM; Darrah K; Zhang F; Wang R; Traina TA; Radke MR; Kaufmann SH; Swisher EM; Guérois R; Modesti M; Sung P; Jasin M; Bernstein KA
    Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2202727119. PubMed ID: 36099300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families.
    Pelttari LM; Kiiski JI; Ranta S; Vilske S; Blomqvist C; Aittomäki K; Nevanlinna H
    Springerplus; 2015; 4():92. PubMed ID: 25918678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
    Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
    PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor.
    Greenhough LA; Liang CC; Belan O; Kunzelmann S; Maslen S; Rodrigo-Brenni MC; Anand R; Skehel M; Boulton SJ; West SC
    Nature; 2023 Jul; 619(7970):650-657. PubMed ID: 37344587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants.
    Lim BWX; Li N; Mahale S; McInerny S; Zethoven M; Rowley SM; Huynh J; Wang T; Lee JEA; Friedman M; Devereux L; Scott RJ; Sloan EK; James PA; Campbell IG
    J Natl Cancer Inst; 2023 Feb; 115(2):181-189. PubMed ID: 36315097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAD51-Mediated DNA Homologous Recombination Is Independent of
    Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAD51B Activity and Cell Cycle Regulation in Response to DNA Damage in Breast Cancer Cell Lines.
    Lee PS; Fang J; Jessop L; Myers T; Raj P; Hu N; Wang C; Taylor PR; Wang J; Khan J; Jasin M; Chanock SJ
    Breast Cancer (Auckl); 2014; 8():135-44. PubMed ID: 25368520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A decade of RAD51C and RAD51D germline variants in cancer.
    Boni J; Idani A; Roca C; Feliubadaló L; Tomiak E; Weber E; Foulkes WD; Orthwein A; El Haffaf Z; Lazaro C; Rivera B
    Hum Mutat; 2022 Mar; 43(3):285-298. PubMed ID: 34923718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.
    Li N; McInerny S; Zethoven M; Cheasley D; Lim BWX; Rowley SM; Devereux L; Grewal N; Ahmadloo S; Byrne D; Lee JEA; Li J; Fox SB; John T; Antill Y; Gorringe KL; James PA; Campbell IG
    J Natl Cancer Inst; 2019 Dec; 111(12):1332-1338. PubMed ID: 30949688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAD51C interacts with RAD51B and is central to a larger protein complex in vivo exclusive of RAD51.
    Miller KA; Yoshikawa DM; McConnell IR; Clark R; Schild D; Albala JS
    J Biol Chem; 2002 Mar; 277(10):8406-11. PubMed ID: 11744692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biallelic
    Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
    JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex formation by the human Rad51B and Rad51C DNA repair proteins and their activities in vitro.
    Lio YC; Mazin AV; Kowalczykowski SC; Chen DJ
    J Biol Chem; 2003 Jan; 278(4):2469-78. PubMed ID: 12427746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
    Sullivan MR; Prakash R; Rawal Y; Wang W; Sung P; Radke MR; Kaufmann SH; Swisher EM; Bernstein KA; Jasin M
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.
    Toh M; Ngeow J
    Oncologist; 2021 Sep; 26(9):e1526-e1537. PubMed ID: 34021944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.